A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma - Report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group

Gino Santini, C. De Souza, S. Aversa, C. Patti, L. Tedeschi, M. Candela, A. Olivieri, T. Chisesi, A. Rubagotti, R. Centurioni, V. Nardi, M. Congiu, M. Gennaro, M. Truini

Research output: Contribution to journalArticle

Abstract

The objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as frontline therapy in aggressive localized non-Hodgkin's lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkin's lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5%) achieved complete remission and 4 (4.3%) partial remission. Three patients (3.2%) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9%, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkin's lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma.

Original languageEnglish
Pages (from-to)719-728
Number of pages10
JournalBrazilian Journal of Medical and Biological Research
Volume37
Issue number5
Publication statusPublished - May 2004

Keywords

  • Localized aggressive non-Hodgkin's lymphoma
  • Radiotherapy
  • Toxicity
  • VACOP-B

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Medicine (miscellaneous)

Fingerprint Dive into the research topics of 'A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma - Report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group'. Together they form a unique fingerprint.

  • Cite this

    Santini, G., De Souza, C., Aversa, S., Patti, C., Tedeschi, L., Candela, M., Olivieri, A., Chisesi, T., Rubagotti, A., Centurioni, R., Nardi, V., Congiu, M., Gennaro, M., & Truini, M. (2004). A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma - Report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group. Brazilian Journal of Medical and Biological Research, 37(5), 719-728.